Yahoo Web Search

Search results

1. pubmed.ncbi.nlm.nih.gov › 21034327Evaluation of 12- and 24-month survival rates after treatment ...

   pubmed.ncbi.nlm.nih.gov › 21034327

   Objective: To evaluate the effectiveness of masitinib for the treatment of nonresectable mast cell tumors (MCTs) in dogs at 12 and 24 months after onset of treatment. Animals: 132 dogs with nonresectable grade 2 or 3 MCTs. Procedures: Dogs received masitinib (12.5 mg/kg/d, PO; n = 106) or a placebo (26). After 6 months, treatment was extended ...

   • Author: Kevin A. Hahn, Alfred M. Legendre, Neil G. Shaw, Brenda Phillips, Gregory K. Ogilvie, Deborah M. Pre...

   • Publish Year: 2010

2. www.ncbi.nlm.nih.gov › pmc › articlesCanine mast cell tumors: diagnosis, treatment, and prognosis

   www.ncbi.nlm.nih.gov › pmc › articles

   Aug 12, 2014 · An early study showed 54% of dogs with a variety of tumors, including sarcoma, carcinoma, myeloma, melanoma, and MCTs, having some response to the drug. 81 A subsequent study in 149 dogs with bulky (nonresectable) grade II or III MCTs showed a 37% response rate in dogs receiving toceranib phosphate (3.25 mg/kg orally every other day) (n=86) vs an 8% response in dogs treated with placebo (n=63 ...

   • Author: Laura D Garrett
   • DOI: 10.2147/VMRR.S41005

   • Publish Year: 2014
   • Publication: Vet Med (Auckl). 2014; 5: 49-58.

3. onlinelibrary.wiley.com › doi › fullResponse to tigilanol tiglate in dogs with mast cell tumors

   onlinelibrary.wiley.com › doi › full

   2 days ago · 1 INTRODUCTION. Mast cell tumor (MCT) is the most common skin tumor in dogs, 1 can involve the dermis, subcutis, or both, and exhibits variable biological behavior, which can be difficult to predict. 2 Standard treatment for a localized, nonmetastatic MCT is surgical excision. 3 Even with incomplete margins, surgery may be curative for low-grade tumors, 4 whereas additional local treatment ...

4. todaysveterinarypractice.com › oncologySimplifying the Approach to Canine Mast Cell Tumors

   todaysveterinarypractice.com › oncology

   • Cached

   Apr 5, 2024 · Several updated recommendations have been proposed. Most prominent is the use of proportional margins. In this approach, a 0.5-cm mass would be removed with 0.5-cm lateral margins, a 1-cm mass with 1-cm margins, and so on up to 2 cm. The recommendation of removing 1 fascial plane deep remains.

5. www.vettimes.co.uk › app › uploadsCutaneous mast cell tumours in canines – part two: treatment

   www.vettimes.co.uk › app › uploads

   SUE MURPHY BVM&S, MSc(Clin Onc), DipECVIM-CA(Onc), MRCVS. in the second of a two-part article, discuss treatment options for mastocytomas in dogs. IN part one of their article the authors looked at mast cell tumours (MCT), reportedly the most common cutaneous tumour in dogs, and covered the diagnosis and staging of the condition (VT44.38).

   • File Size: 821KB

   • Page Count: 14

6. www.dvm360.com › view › treatment-options-canineTreatment options for canine cutaneous mast cell tumors - dvm360

   www.dvm360.com › view › treatment-options-canine

   • Cached

   Apr 1, 2005 · In one recent study, 35 dogs with nonresectable cutaneous mast cell tumors were treated with oral prednisone and palliative radiation therapy.32 This palliative treatment protocol provided an impressive overall response rate of 88.5%, with 12 complete responses and 19 partial responses.

7. People also ask

   How long does Masitinib last in dogs with nonresectable mast cell tumors?

   • Hahn KA, Legendre AM, Shaw NG, et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res. 2010;71(11):1354–1361.

   Canine mast cell tumors: diagnosis, treatment, and prognosis

   www.ncbi.nlm.nih.gov/pmc/articles/PMC7337164/

   See all results for this question

   Is Masitinib safe for dogs with MCT?

   • Conclusions and Clinical Importance: Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT. Key words: Dog; KIT; Mast cell tumor. cell tumors (MCT) are the most common cu-taneous tumors in dogs, accounting for 7–21% of all skin tumors.

   Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tu…

   www.ab-science.com/file_bdd/content/1265603421_jvetinternmed2008hahn.pdf

   See all results for this question

   Does Masitinib cause tumors in dogs?

   • Dogs receiving first-line treatment with masitinib com-prised 42.1% of the trial population, and the remaining 57.9% had received previous medical treatment for MCT. The majority of dogs enrolled in this study (65.3%) had nonresectable tumors, and the remainder (34.6%) had tumors that were recurrent after surgery.

   Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tu…

   www.ab-science.com/file_bdd/content/1265603421_jvetinternmed2008hahn.pdf

   See all results for this question

   How long can a dog survive a mast cell tumor?

   • With surgical resection only, the percentages of dogs surviving 1,500 days after diagnosis have been reported to be 83%, 44%, and 6% for grades I, II, and III tumors, respectively.2 Grade I mast cell tumors tend to be locally confined to the skin and nonmetastatic.

   Treatment options for canine cutaneous mast cell tumors - dvm360

   www.dvm360.com/view/treatment-options-canine-cutaneous-mast-cell-tumors

   See all results for this question

   What are the treatment options for noncurable mast cell tumors in dogs?

   • Several palliative treatment options exist for managing noncurable mast cell tumors in dogs, including systemic chemotherapy, palliative radiation, and intralesional triamcinolone. Although potentially useful as an adjuvant to surgery, systemic chemotherapy has been traditionally indicated to treat metastatic and nonresectable mast cell tumors.

   Treatment options for canine cutaneous mast cell tumors - dvm360

   www.dvm360.com/view/treatment-options-canine-cutaneous-mast-cell-tumors

   See all results for this question

   How long does Masitinib last?

   • In one study assessing masitinib in non-metastatic recurrent or non-resectable intermediate or high-grade MCT, masitinib increased the overall time to progression from 75 days (placebo) to 118 to 253 days, with minimal side effects42.

   Cutaneous mast cell tumours in canines – part two: treatment - Vet Times

   www.vettimes.co.uk/app/uploads/wp-post-to-pdf-enhanced-cache/1/cutaneous-mast-cell-tumours-in-canines-part-two-treatment.pdf

   See all results for this question

8. www.ab-science.com › file_bdd › contentMasitinib is Safe and Effective for the Treatment of Canine ...

   www.ab-science.com › file_bdd › content

   Key words: Dog; KIT; Mast cell tumor. Mast cell tumors (MCT) are the most common cu-taneous tumors in dogs, accounting for 7–21% of all skin tumors. The behavior and progression of MCT are highly heterogeneous; some MCT are behaviorally benign, develop slowly, and persist for years without in-creasingin size, whereas others exhibit aggressive ...